Abstract:We have read with great interest of the recently published article entitled “Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension” by García-Lucio J et al. [ [1] Garcia-Lucio J. Tura-Ceide O. Del Pozo R. Blanco I. Pizarro S. Ferrer E. et al. Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension. Int. J. Cardiol. 2017; 228: 238-243 Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar ]. In this study, the number of circulating endothelial progenitor cells (EPC) is lower in naïve pulmonary artery hypertension (PAH) patients, and treatment of PAH-targeted drugs increased EPC levels in the blood of PAH patients. However, there is no elevation of circulating EPC in chronic thromboembolic pulmonary hypertension patients. Previous reports suggest that the level of circulating EPC is positively correlated with pulmonary artery pressure [ [2] Foris V. Kovacs G. Tscherner M. Olschewski A. Olschewski H. Biomarkers in pulmonary hypertension: what do we know?. Chest. 2013; 144: 274-283 Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar ]; moreover, EPC from PAH patients treated with treprostinil showed a more proliferative phenotype and more angiogenic potential [ [3] Smadja D.M. Mauge L. Gaussem P. d'Audigier C. Israel-Biet D. Celermajer D.S. et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis. 2011; 14: 17-27 Crossref PubMed Scopus (45) Google Scholar ]. Animal study showed that infusion of EPC from monocrotaline-induced murine PAH model increases the pulmonary artery pressure of healthy animals [ [4] Aliotta J.M. Pereira M. Wen S. Dooner M.S. Del Tatto M. Papa E. et al. Bone marrow endothelial progenitor cells are the cellular mediators of pulmonary hypertension in the murine monocrotaline injury model. Stem Cells Transl. Med. 2017; 6: 1595-1606 Crossref PubMed Scopus (16) Google Scholar ]. These may indicate that the reduction of EPC number and dysfunction of EPC are involved in the pathogenesis of PAH; targeted therapy for PAH may decrease pulmonary artery remodeling at least partially through improving the proliferation and function of EPCs. Recent studies showed that modulating intracellular genes or microRNAs is sufficient to improve EPC differentiation and proliferation. Excitingly, gene-enhanced EPC therapy is entering clinical trials for human PAD [ [5] Granton J. Langleben D. Kutryk M.B. Camack N. Galipeau J. Courtman D.W. et al. Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial. Circ. Res. 2015; 117: 645-654 Crossref PubMed Scopus (102) Google Scholar ]. In conclusion, modulation of EPC proliferation and function may serve as a new strategy for PAH therapy.

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Interruption of CD40 Pathway Improves Efficacy of Transplanted Endothelial Progenitor Cells in Monocrotaline Induced Pulmonary Arterial Hypertension.

Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients with Idiopathic Pulmonary Arterial Hypertension: a Pilot Randomized Controlled Trial.

Autologous Endothelial Progenitor Cells Transplantation for the Therapy of Primary Pulmonary Hypertension

Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: Open-label pilot study

Paracrine Effects Of Bone Marrow-Derived Endothelial Progenitor Cells: Cyclooxygenase-2/Prostacyclin Pathway In Pulmonary Arterial Hypertension

Modulation of EPC: A New Hope for Pulmonary Artery Hypertension Treatment

Comments to the Article "diverse Contribution of Bone Marrow-Derived Late-Outgrowth Endothelial Progenitor Cells to Vascular Repair under Pulmonary Arterial Hypertension and Arterial Neointimal Formation".

Endothelial progenitor cells in age-related vascular remodeling.

The Differentiation of Pluripotent Stem Cells Towards Endothelial Progenitor Cells - Potential Application in Pulmonary Arterial Hypertension.

Combined Hypoxia Inducible Factor-1Α and Homogeneous Endothelial Progenitor Cell Therapy Attenuates Shunt Flow–induced Pulmonary Arterial Hypertension in Rabbits

Intravenous infusion of autologous endothelial progenitor cells in treatment of primary pulmonary hypertension

Using Human Pluripotent Stem Cell Differentiated Endothelial Cells to Study the Differential Regulation in PAH

Stem/Progenitor Cells And Pulmonary Arterial Hypertension

High shear stress-induced pulmonary hypertension alleviated by endothelial progenitor cells independent of autophagy

Stem/Progenitor Cells and Pulmonary Arterial Hypertension.

Therapeutic effect of eNOS-transfected endothelial progenitor cells on hemodynamic pulmonary arterial hypertension

EPCs in vascular repair: how can we clear the hurdles between bench and bedside?

Panorama of artery endothelial cell dysfunction in pulmonary arterial hypertension

Endothelial cells in the pathogenesis of pulmonary arterial hypertension